天气预报   今天: 厦门 阵雨 16-19℃ 风力2级 无持续风向 降水概率0%
  中文网站  |  English

首页 > 中心简介 > 研究团队

吴婷

吴 婷,博士,副教授,1994年毕业于上海医科大学药物化学专业;2000年毕业于复旦大学药学院(原上海医科大学药学院),获生物合成药物化学专业博士学 位。2003年1月起进入厦门大学。主要研究方向为疫苗临床试验和传染病的流行病学研究,目前做为项目负责人开展人乳头瘤病毒(HPV)16/18型双价 疫苗和HPV6/11双价疫苗的I-III期临床研究及相关流行病学研究。作为主要研究人员之一完成国家一类新药戊型肝炎病毒重组疫苗III期临床试验, 该疫苗现已在中国成功上市。2010年受邀担任欧盟第7框架“疾病控制工具”(DISCONTOOLS- EU FP7)项目中食物源性戊型肝炎病毒专家组成员。作为主要研究人员主持或参与多项国家传染病重大科技专项、国家863项目、福建省科技重大专项等多个项 目。

目前开展的主要研究项目:

1、重组人乳头瘤病毒(HPV)16/18型双价疫苗临床研究;

2、重组人乳头瘤病毒(HPV)6/11型双价疫苗临床研究;

3、重组戊型肝炎疫苗长期保护性和免疫持久性的研究;

4、重组戊型肝炎疫苗在特殊人群如慢性肝病患者、孕妇中的临床研究;

5、乙肝表面抗原携带者的转归研究;

6、乙肝表面抗原携带者重叠感染戊肝的研究

7、巨细胞病毒流行病学调查

 

Wu Ting, Ph.D., Associate Professor. She got herbachelor and Ph.D. degree in Fudan University, school of Pharmacy (formerShanghai Medical University), she became a staff in Xiamen University form Jan.2003. Her present research focuses on vaccine clinical trial and epidemiologystudy of infectious diseases. As one of the core team member, she participatedthe large-scale, double-blind, randomized, placebo-controlled phase III clinicaltrial of recombinant Hepatitis E vaccine, which has now been approved in Chinaand became the first commercialized Hepatitis E vaccine in the world. Her mainpresent projects include:

1.Clinical trial of recombinant human papillomavirus virus type16/18 vaccine;

2.Clinical trial of recombinant human papillomavirus virus type 6/11vaccine;

3.Study on long term efficacy and immune persistency of recombinantHepatitis E vaccine;

4.Study on efficacy and safety of recombinant Hepatitis E vaccine inhigh risk population such as chronic liver diseases, pregnant women;

5.Study on long term outcome of HBsAg carriers;

6.Study on superinfection of HEV in HBsAg carriers.

7.Epidemiologystudy on Cytomegalovirus (CMV)

 

从事或正在承担的研究项目及所负责任:

863项目“ORF7基因敲除的减毒水痘活疫苗等几种新疫苗的研发(课题编号:2012AA02A408)”中任务“重组人乳头瘤病毒(HPV)16/18型双价疫苗的I/II/III期临床试验”的负责人

重大新药创制“重组戊型肝炎疫苗IV期临床试验(课题编号:2013ZX09101017)”主要执行人

863项目诊断试剂关键性原辅材料的研制(课题编号:2011AA02A114):项目负责人

艾 滋病和病毒性肝炎等重大传染病防治项目“乙型病毒性肝炎免疫预防新策略研究”(2012.1-2015.12,课题编号: 2012ZX10002001):为子课题五中任务“HBsAg阳性人群的长期转归研究”(任务编号:2012ZX10002001-005-003)的 任务负责人,

863重大项目(2007-2010):“重组戊型肝炎疫苗三期临床研究”(2006AA02A209),主要参加者,已结题。该课题完成了戊肝疫苗的III期临床研究,结果发表于《Lancet》。

 

发明专利:

l吴婷,伍小路,罗文新,张军,夏宁邵. 用于免疫或制备单克隆抗体的方法和组合物. 中国发明专利申请号:200610081554.4,授权日:2012.6

代表论文:

[1]Wu T, Zhu FC, Huang SJ, Zhang XF, WangZZ, Zhang J*, Xia NS*. Safety ofhepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology,2012, 55(6): 2038, doi: 10.1002/ hep.25522.(IF:11.665).

[2]Wu T*, Huang SJ, Zhu FC, Zhang XF, Ai X, Yan Q, Wang ZZ, YangCL, Jiang HM, Liu XH, Guo M, Du HL, Ng MH, Zhang J, Xia NS. Immunogenicity and safety of hepatitis Evaccine in healthy hepatitis B surface antigen positive adults. HumanVaccines & Immunotherapeutics, 2013, 9(11): 1-6 (IF:3.136, 通讯作者)

[3]Wu T, Li SW, Zhang J, Ng MH, Xia NS,Zhao QJ*. Hepatitis E vaccine development, A 14 year odyssey. HumanVaccines & Immunotherapeutics, 2012, 8:823-827.(IF:3.136)

[4]Wu T, Zhang J, Xia NS*. Rationallyrespond to post-vaccination adverse events. Sci China Life Sc, 2014, doi:10.1007/s11427-014 -4623-4. (IF:2.02)

[5]Zhao H, Lin ZJ, Huang SJ, Li J,Liu XH, Guo M, Zhang J, Xia NS, Pan HR*, WuT*, Li CG*. Correlation between ELISA and pseudovirion-basedneutralisation assay for detecting antibodies against human papillomavirusacquired by natural infection or by vaccination. Human Vaccines &Immunotherapeutics, 2014, 10 (3)(IF:3.136, 共通讯作者)

[6]Zhu FC, Huang SJ, Wu T, Zhang XF, Wang ZZ, Ai X, YanQ, Yang CL, Cai JP, Jiang HM, Wang YJ, Ng MH, Zhang J*, Xia NS. Epidemiology ofzoonotic hepatitis E: a community-based surveillance study in a ruralpopulation in China. PLoS ONE, 2014, 9(1): e87154. doi:10.1371/journal.pone.0087154(IF:4.411)

[7]Hu YM, Huang SJ, Chu K, Wu T, Wang ZZ, Yang CL, Cai JP,Jiang HM, Wang YJ, Guo M, Liu XH, Huang HJ, Zhu FC, Zhang J*, Xia NS. Safety ofan Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18)L1 virus-like particle vaccine: an open-label phase I clinical trial. HumanVaccines & Immunotherapeutics, 2014, 10(2): 1–7.(IF:3.136)

[8]Zhang J, Zhang XF, Zhou C, WangZZ, Huang SJ, Yao X, Liang ZL, Wu T,Li JX, yan Q, Yang CL, Jiang HM, Huang HJ, Xian YL, Shih JW, Ng MH, Li YM, WangJZ*, Zhu FC*, Xia NS*. Protection against hepatitis E virus infection bynaturally acquired and vaccine induced immunity. Clin Microbiol Infect. 2013,Oct 5. doi: 10.1111/1469-0691. 12419. [Epub ahead of print](IF:4.54)

[9]Zhang J, Li SW, Wu T, Zhao Q, Ng MH, Xia NS*.Hepatitis E virus: neutralizing sites, diagnosis, andprotective immunity. Rev Med Virol, 2012, 22(5): 339-349.doi: 10.1002/rmv.1719.(IF:7.2)

[10]Zhao Q, Zhang J, Wu T,Li SW, Ng MH, Xia NS*, Shih JW*. Antigenic determinants of hepatitis E virusand vaccine-induced immunogenicity and efficacy. J Gastroenterol. 201348(2):159-68. doi: 10.1007/s00535-012-0701-1. (IF:4.16)

[11]Zhang J, Shih JW*, Wu T,Li SW, Xia NS. Development of the hepatitis e vaccine: from bench to field. SeminLiver Dis. 2013 Feb; 33(1):79-88. (IF: 7.05)

[12]Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, YangCL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, ShihJW, Xia NS. Efficacy and Safety of aRecombinant Hepatitis E Vaccine in Healthy Adults: A Large-scale, Double-blind,Randomized, Placebo Controlled Phase III Clinical Trial. Lancet, 2010, 376: 895–902. (IF:33.633)

[13]Huang SJ, Zhang XF, Jiang HM, Yan Q, Ai X, Wang YJ, Cai JP, JiangL, Wu T, Wang ZZ, Guan L,Shih JW, Ng MH, Zhu FC, Zhang J, Xia NS. Profile of Acute Infectious Markers inSporadic Hepatitis E, PLoS ONE, 2010, 5(10): e13560.doi:10.1371 (IF:4.411)

[14]Wu T, Zhang J, Su ZJ, Liu JJ, Wu XL, Wu XL, Lin CX, Ou SH, Yan Q, Shih JW, XiaNS. The specific cellular immune responsein hepatitis E patients. Intervirology, 2008, 51, 322-327.

[15]Wu T, Wu XL, Ou SH, Lin CX, Cheng T, Li SW, Ng MH, Zhang J, Xia NS. Difference of T cell and B cell activationin two homologous proteins with similar antigenicity but great distinctimmunogenicity. Molecular Immunology, 2007, 44(12): 3261-3266

[16]Wu T, Chen M, Ou SH, ChengT, Zhang J, Xia NS.Immune response induced by differentcombined immunization of HBsAg vaccine.Intervirology, 2007, 50(5): 336-340

[17]Wu T, Zhang J *, Wu XL, Lin CX, Xie MH, Ge SX,Ng MH, Xia NS. Identification of a dominant H-2d restricted Th epitope oncapsid protein of hepatitis E virus. J Clin Virol, 2006; S159

[18]He S, Miao J, Zheng Z, Wu T, XieM, Tang M, Zhang J, Ng MH, Xia N. Putative receptor-binding sites of hepatitisE virus. J Genvirol, 2008; 89: 245-249.

[19]Chen M, Cheng T, Xu CY, WuT, Ou SH, Zhang T, Zhang J, Xia NS. Hydrophobicity of reactive site loop of SCCA1affects its binding to hepatitis B virus. World J Gastroenterol. 2005, 11(19) : 2864-2868.

[20]Cheng T, Xu CY, Wang YB,Chen M, Wu T, Zhang J, Xia NS A rapid and efficient method to express targetgenes in mammalian cells by baculovirus. World JGastroenterol. 2004, 10(11) : 1612-1618.

[21]吴婷,张军,夏宁邵. 科学对待疫苗接种后不良事件,中国科学C辑,2014,doi: 10.1360/052014-1

[22]张军,吴婷,夏宁邵. 戊型肝炎诊断、预防及治疗新进展, 传染病信息,2013,26(2):89-92

[23]吴婷,江浪. 戊型病毒性肝炎研究进展,中国疫苗和免疫,2009, 15(4):375-378

[24]吴婷,等. 戊型肝炎病毒重组颗粒性蛋白疫苗在小鼠体内诱导的免疫应答研究. 病毒学报,2005,21(6): 428-433

[25]吴婷,等. 荧光素标记检测乙型肝炎病毒表面抗原特异性杀伤T淋巴细胞方法的探讨. 病毒学报,2005,21(2):121-125

[26]吴婷,等. 不同HBsAg疫苗联合免疫后诱导小鼠细胞和体液免疫应答的研究. 细胞与分子免疫学杂志. 2006, 22(5) : 568-570.

[27]吴婷,等. 重组痘苗病毒对不同哺乳动物细胞株的感染效率及EGFP表达水平研究. 厦门大学学报(自然科学版),2005,44(6): 866-869

[28]林春鑫,吴婷,等. 戊肝病毒表位肽特异性Th细胞可增强其载体蛋白免疫原性. 生物工程学报, 2007,23(2):139-143

[29]伍小路,吴婷,等. 戊型肝炎病毒颗粒性蛋白疫苗H-2d限制性Th表位的筛选. 病毒学报,2006,22(3):176-179

[30]欧山海,吴婷,等. 一个包含HCVIRES的高效真核双顺反子表达载体的构建. 中国人兽共患病杂志,2005,21(9): 783-787

 

Conference Report:

[1]11th Annual General Meeting & Conferenceof DCVMN, Hyderabad, India , 2010.9.16, Hepatitis E Vaccine (Hecolin)-Not a Moment Too Soon.

[2]MICROCON 2010, XXXIV National Conference ofIndian Association of Medical Microbiologists, Kolkata, India, 2010.11.28,Hepatitis E- a Neglected Disease.

[3]Asian-Oceania Research Organization onGenital Infection and Neoplasia (AOGIN) 2014, Beijing China, 2014.4.26, Correlationbetween ELISA and pseudovirion-based neutralisation assay for detectingantibodies against human papillomavirus acquired by natural infection or byvaccination.

厦门大学备案号:D200327 版权所有© 厦门大学